National Institute of Allergy anf Infectious Diseases - Thursday, Nov. 30, 2000
Wendy Wertheimer, Office of AIDS Research Leslie Fink, NIAID Office of Communications and Public Liaison
As communities around the globe commemorate World AIDS Day, the National Institutes of Health (NIH) will announce a new initiative and strategic plan for global research on HIV/AIDS aimed at slowing the disaster and reversing its destruction of communities, economies and nations worldwide.
National Institute of Allergy & Infectious Diseases - Monday, Nov. 20, 2000
Sam Perdue (301) 402-1663 sp189u@nih.gov
Proteins that help clean and organize the inside of certain T cells may assist HIV in spreading through the body, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) report in the November 21 issue of the Proceedings of the National Academy of Sciences.
National Institute of Allergy & Infectious Diseases - Wednesday, Nov. 15, 2000
Jeff Minerd (301) 402-1663 jminerd@nih.gov
Two groups of people especially intrigue AIDS researchers: those who resist HIV infection despite repeated exposure to the virus and those who progress very slowly to AIDS after infection. Understanding what makes these individuals different could lead to new vaccines and treatments, and a study published this week in the early online edition of the journal AIDS brings scientists closer to that goal.
Naitonal Institute of Allergy & Infectious Dieseases - Wednesday, Oct. 25, 2000
Laurie K. Doepel (301) 402-1663 doepel@nih.gov
Interleukin-2 (IL-2), an immune system protein, has been shown to increase the number of CD4+ T cells in many people with HIV infection. Studies conducted before the era of potent antiretroviral therapy, however, suggested IL-2 was less effective in patients with very low levels of these cells, which HIV destroys.
National Institute of Allergy & Infectious Diseases - Wednesday, Sept. 20, 2000
Laurie K. Doepel (301) 402-1663 doepel@nih.gov
Vaccines designed to trigger an immune response to a small HIV protein called Tat could be a promising way to fend off the virus, intriguing new data suggest. According to a report in this week's journal Nature, "killer" T cells targeted to the Tat protein can effectively contain simian immunodeficiency virus (SIV), the monkey version of HIV, during the natural course of early infection.
National Institute of Allergy & Infectious Diseases - Friday, Sept. 8, 2000
Laurie K. Doepel, 301-402-1663 Sara Byars, 301-496-2563
Investigators at the National Institutes of Health (NIH) have demonstrated that a disabling bone disorder, osteonecrosis of the hip, is surprisingly common among patients with HIV infection. Concern that the disorder might be a new and unrecognized complication of HIV infection prompted the investigation, a collaboration between the NIH Clinical Center and the National Institute of Allergy and Infectious Diseases (NIAID).
National Institute of Allergy & Infectious Diseases - Thursday, July 13, 2000
Sam Perdue (301) 402-1663 sp189u@nih.gov
DURBAN, South Africa- A team of scientists from the United States and Uganda reported today that the inexpensive AIDS drug nevirapine, when given to both mother and child around the time of birth, greatly reduces mother-to-infant transmission of HIV up to a year after the medicine was given.
National Institute of Allergy & Infectious Diseases - Wednesday, July 12, 2000
Gregory Roa (in U.S.) (301) 402-1663 greg.roa@nih.gov
The worldwide search for an HIV vaccine received a boost today as the National Institute of Allergy and Infectious Diseases (NIAID) announced the formation of the new international HIV Vaccine Trials Network (HVTN). The HVTN will provide a comprehensive, clinically based network to develop and test preventive HIV vaccines.
National Institute of Allergy & Infectious Diseases - Tuesday, July 11, 2000
Greg Folkers (in U.S.) (301) 496-2263 gfolkers@nih.gov
For some HIV-infected patients whose plasma levels of virus have fallen to undetectable levels while on highly active antiretroviral therapy (HAART), it may prove feasible to move from a continuous HAART regimen to intermittent therapy in which an individual discontinues, then resumes HAART in a pre-planned, cyclic fashion.
National Institute of Allergy & Infectious Diseases - Saturday, July 8, 2000
Laurie K. Doepel (301) 402-1663 doepel@nih.gov
The first randomized, controlled trial of interleukin-2 (IL-2) therapy conducted in the era of highly active antiretroviral therapy, or HAART, has found that combining the immune-based therapy with potent antiretrovirals markedly boosts CD4+ T-cell counts without increasing the amount of HIV in the blood.
National Institute of Allergy & Infectious Diseases - Wednesday, March 15, 2000
Sam Perdue (301) 402-1663 sperdue@nih.gov
For reasons largely unknown, a small number of HIV-infected individuals remain symptom-free long after AIDS normally would have appeared. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) and their co-workers now report how a small subgroup of these so-called long-term nonprogressors (LTNPs) may avoid disease.
National Institute of Allergy & Infectious Diseases - Thursday, March 2, 2000
Sam Perdue (301) 402-1663 sperdue@nih.gov
The National Institute of Allergy and Infectious Diseases (NIAID) today released its latest report on the state of vaccine research and development. Since its origins in 1981, The Jordan Report has regularly updated researchers, policy makers and interested constituents on the latest accomplishments and future directions of vaccine research.
This information is designed to support, not replace, the relationship that exists between you and your doctor.